Literature DB >> 22002750

Autotaxin and LPA receptor signaling in cancer.

Anna J S Houben1, Wouter H Moolenaar.   

Abstract

Lysophosphatidic acid (LPA; monoacyl-glycerol-3-phosphate) is a lipid mediator that functions as a mitogen and motility factor for many cell types. LPA signals through six specific G protein-coupled receptors, named LPA(1-6), which trigger both overlapping and distinct signaling pathways. LPA is produced from extracellular lysophosphatidylcholine by a secreted lysophospholipase D, named autotaxin (ATX), originally identified as an "autocrine motility factor" for tumor cells. ATX-LPA signaling is vital for embryonic development and promotes tumor formation, angiogenesis, and experimental metastasis in mice. Elevated expression of ATX and/or aberrant expression of LPA receptors are found in several human malignancies, while loss of LPA(6) function has been implicated in bladder cancer. In this review, we summarize our present understanding of ATX and LPA receptor signaling in cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002750     DOI: 10.1007/s10555-011-9319-7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  102 in total

1.  c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

Authors:  Stefano Sioletic; Jeffrey Czaplinski; Lan Hu; Jonathan A Fletcher; Christopher D M Fletcher; Andrew J Wagner; Massimo Loda; George D Demetri; Ewa T Sicinska; Eric L Snyder
Journal:  J Pathol       Date:  2014-08-01       Impact factor: 7.996

2.  Expression of lysophosphatidic acid receptor 5 is necessary for the regulation of intestinal Na+/H+ exchanger 3 by lysophosphatidic acid in vivo.

Authors:  Kayte A Jenkin; Peijian He; C Chris Yun
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-24       Impact factor: 4.052

3.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

4.  Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Authors:  Shih-Chi Su; Xiaoxiao Hu; Patrick A Kenney; Megan M Merrill; Kara N Babaian; Xiu-Ying Zhang; Tapati Maity; Shun-Fa Yang; Xin Lin; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

5.  Uncovering unique roles of LPA receptors in the tumor microenvironment.

Authors:  Sue-Chin Lee; Yuko Fujiwara; Gabor J Tigyi
Journal:  Receptors Clin Investig       Date:  2015

Review 6.  Clinical significance of the integrin α6β4 in human malignancies.

Authors:  Rachel L Stewart; Kathleen L O'Connor
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

7.  Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood-brain barrier.

Authors:  David B Banks; Gary Ny Chan; Rebecca A Evans; David S Miller; Ronald E Cannon
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-27       Impact factor: 6.200

Review 8.  Bioactive lysophospholipids: role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma.

Authors:  Ponugoti Vasantha Rao
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-27       Impact factor: 2.671

9.  Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.

Authors:  Ingun Heiene Tveteraas; Monica Aasrum; Ingvild Johnsen Brusevold; John Ødegård; Thoralf Christoffersen; Dagny Sandnes
Journal:  Tumour Biol       Date:  2015-09-19

10.  Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.

Authors:  Aihua Xu; Md Ahsanul Kabir Khan; Fangzhi Chen; Zhaohui Zhong; Han-Chun Chen; Yuanda Song
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.